U.S. Markets closed

Enlivex Therapeutics Ltd. (ENLV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.62+0.26 (+3.11%)
At close: 1:00PM EST
Sign in to post a message.
  • J
    J
    Do you realize that they're technically already proving the efficacy of this product on Sepsis patients through their Covid testing? I know that they're technically separate trials altogether, but since both trials are effectively testing the use of Allocetra to treat sepsis patients with or without Covid, can these trials coincide?

    I don't know anything about testing guidelines, but if a Covid patient with sepsis was treated with Allocetra, would they count as a patient for both trials? If so, then they might be able to meet their 160 patient testing criteria for the Sepsis Phase IIB trial easily, and much more quickly than they would have otherwise been able to recruit patients otherwise.
  • D
    David
    1.7 million cases of Sapsis in the US in 2017 and total cases of 49 million around the world. A cording to the World's Health Organization, Sapsis responsible for 20% of the globe death factors. India alone got 11 milion Sepsis cases a year. It will take some time but Enlivex potential is huge.
    Bullish
  • O
    Owen
    Shai Novik, executive chairman, estimates revenue of about $1Billion annually if Allocetra is approved for covid-19 patients in critical condition. This is unchanged by the positive vaccine news as he explained at the H.C. Wainwright’s 6th Annual Israel Conference this morning...
    Bullish
  • ש
    שרון
    we are not a vaccine. we are a treatment.!!
  • m
    matt
    C’mon !!!!!
    Bullish
  • T
    Tomer
    guys thank you. this has been a fun ride. this stock will crash soon. lost 50% and once vaxines will be used this stock will be worth 4$.
    no good news will help this one. a lost cause. hope you all get out with some cash. see ya on the other side.
  • A
    Anonymous
    Isn’t sepsis study supposed to start in November?
  • O
    Owen
    Each year, at least 1.7 million adults in America develop sepsis. Nearly 270,000 Americans die as a result of sepsis. 1 in 3 patients who dies in a hospital has sepsis. This drug Allocetra is a very big deal. Be patient, let the doctors do their thing.
  • v
    vince
    Not to repeat what I said weeks ago; but the sepsis trials is the potential gamechanger for enlv :) IMHO...results for the next 160 (after recruitment on phase 2b) may be in 60-90 days......not discounting covid but they're late in the game on that one with a lot of competition and $$ being thrown around. covid success just makes this better IMHO.....but sepsis is something that NOBODY has been able to figure out yet......gamechanger possibility :)
  • E
    Erane21
    Very good news one hour ago!
  • C
    Chk is gonna dowhat?
    How much is ENLV worth for Sepsis ???
  • a
    asi
    Important and exclusive news for $ENLV investors outside Israel
    Tonight on Israeli television, Professor Dror Maboch (the developer Allocestra drug) announced that the first two patients from the Phase Two trial of the Allocestra drug are feeling well.
    Bullish
  • T
    Tomer
    guys do not forget that the webinar is tomorrow!
    Bullish
  • ש
    שרון
    now from a sure thing it's a casino
    Bullish
  • E
    Erane21
    shai novick(executive chairman) said they recruited more than 2 patients.
  • E
    Erane21
    If they going to do a webiner-maybe that means they going to publish some good news for us? $$$$
  • e
    erez
    Very brilliant people I was really impressed from the zoom meeting.
    
  • A
    Alan
    I expected it to move quite a bit after the meeting
  • K
    Kev US
    Anyone know the different between Remdesivir from Gilead and Allocetra since Remdesivir has been approved today for treatment in US in hospital setting for Mid/severe Covid patients to cut the recovery time.
    Since Enlivex needs to expand to US as patent due in Q4/2020. Hopefully can get EUA in Israel, EU and US as well..
  • A
    At
    A treatment will still be needed. Also, this is not the only thing coming down the pipeline.